RNAZ Intrinsic Valuation and Fundamental Analysis - Transcode Therapeutics Inc

Watchlist Manager

Watchlist

Price: 1.63 USD -12.37% Market Closed

Market Cap: $27.1m

	Transcode Therapeutics Inc NASDAQ:RNAZ	US
	Bank Central Asia Tbk PT IDX:BBCA	ID
	Pharol SGPS SA F:PTCA	PT
S	Smart Concrete PCL SET:SMART	TH
H	Ho Hup Construction Company Bhd KLSE:HOHUP	MY

Intrinsic Value

RNAZ doesn't have a meaningful market cap.

Is RNAZ undervalued or overvalued?

See the intrinsic value estimate for Transcode Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.

Do our valuations actually work? See backtest results .

RNAZ Intrinsic Value

Unlock

Today vs. history

See how today’s valuation compares with RNAZ’s past valuations and how the stock performed after similar periods.

See what happened next Free account required

Track Buy Zone

20% below Intrinsic Value

Get notified when the price drops into your buy zone

Intrinsic Value Locked

Margin of Safety 20% Locked

Current Price $1.63

Or choose another margin of safety

0% below Intrinsic Value

10% below Intrinsic Value

30% below Intrinsic Value

40% below Intrinsic Value

50% below Intrinsic Value

Custom

Fundamental Analysis

What Transcode Therapeutics Does

Biotechnology Health Care

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.

Headquarters: United States of America US
Employees: 12
IPO date: Apr 28, 2021